Livedoid vasculitis
https://en.wikipedia.org/wiki/Livedoid_vasculitis
☆ AI Dermatology — Free ServiceYn 'e 2022 Stiftung Warentest-resultaten út Dútslân wie de konsuminttefredenheid mei ModelDerm mar wat leger dan mei betelle telemedisynkonsultaasjes. 

It kin begelied wurde troch pine.
relevance score : -100.0%
References
Livedoid vasculopathy: A review with focus on terminology and pathogenesis 36285834 NIH
Livedoid vasculopathy is in seldsume hûdbetingst karakterisearre troch pynlike sweren dy't hieltyd weromkomme op de legere skonken.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy: A review of pathogenesis and principles of management 27297279Livedoid vasculopathy is in seldsume hûdkondysje dy't weromkommende wûnen op 'e legere skonken feroarsaket, wêrtroch bleke littekens dy't bekend binne as atrophie blanche. Wylst de krekte oarsaak noch ûndúdlik is, wurdt leard dat ferhege bloedstolling (hypercoagulability) de wichtichste faktor is, mei ontsteking in sekundêre rol. Faktors dy't bydrage oan stolling omfetsje de folgjende - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Yn biopsieën toant de beting bloedklots yn 'e skippen, dikking fan de skippenwâlen, en littekens. Behanneling omfettet in mearsidige oanpak dy't rjochte is op it foarkommen fan bloedklots mei medisinen lykas antiplatelet-medisinen, antikoagulaants, en fibrinolytyske terapy. Ferskate medisinen kinne brûkt wurde foar dizze hûdbetingsten - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid Vasculopathy 32644463 NIH
Livedoid vasculopathy is in seldsume tastân dêr't lesions foarkomme op beide skonken. De formaasje fan bloedklots yn lytse bloedfetten wurdt nei alle gedachten feroarsake troch ferhege koagulaasje en fermindere fibrinolise, tegearre mei skea oan de endotheliale lining. It komt faker foar by froulju, foaral tusken de 15 en 50 jier. Ophâlde fan roken, fersoargje fan wûnen, en it brûken fan medisinen lykas antikoagulaasjemiddels en antiplatelet-middels binne effektyf west.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.